Connie Johnson Breast Cancer Research Lab

Selected Publications

Hickey TE, Selth LA, Chia KM, Milioli HH, Roden D, Laven-Law G, Jindal S, Hui M, Ebrahimie E, Birrell SN, Stelloo S, Caldon CE, Finlay-Schultz J, Abdel-Fatah TM, Ellis IO, Zwart W, Palmieri C, Sartorius CA, Swarbrick A, Lim E, Carroll JS, Tilley WD. The Androgen Receptor is a Tumour Suppressor in Estrogen Receptor Positive Breast Cancer. Nature Medicine. Jan 2021 

Chia KM, Freelander A, Kumar S, Portman NLim E. Estrogen receptor positive breast cancer patient derived xenograft models in translational research. Current Opinion in Endocrine and Metabolic Research. 23rd Oct 2020.

Wu SZ, Roden D, Wang CF, Cazet A, Al-Eryani G, Harvey K, Holliday H, Murphy K, Pereira B, Bartonicek N, Hou R, Torpy J, Junankar S, Hui M, Gluch L, Beith J, Parker A, Robbins E, Segara D, Mak C, Cooper C, Warrier S, Powell J, O’Toole S, Cox T, Timpson P, Forrest A, Lim E, Liu XS, Swarbrick A. Single-cell analysis reveals diverse stromal subsets associated with immune evasion in breast cancer. Embo J. 2020 Oct 1;39(19)

Portman N*, Milioli HH*, Alexandrou S, Coulson R, Yong A, Fernandez KJ, Chia KM, Segara D, Parker A, Swarbrick A, Haupt A, Haupt Y, Tilley WD, Swarbrick A, Caldon CE*, Lim E*. Synergistic targeting of estrogen-receptor positive breast cancers by MDM2 inhibition in combination with endocrine therapy or CDK4/6 inhibition. Breast Cancer Research. 2020 Aug 12;22(1):87.

Baker LA, Holliday H, Roden D, Krisp C, Wu SZ, Junankar S, Serandour AA, Mohammed H, Nair R, Sankaranarayanan G, Law AMK, McFarland A, Simpson PT, Lakhani S, Dodson E, Selinger C, Anderson L, Samimi G, Hacker NF, Lim E, et al. Proteogenomic analysis of Inhibitor of Differentiation in basal-like breast cancer. Breast Cancer Research. 2020 Jun 11;22(1):63

Milioli HH, Alexandrou S, Lim E, Caldon C. Cyclins E1 and E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets. Endocrine-Related Cancer. 2020 May;27(5):R93-112.

Chen J*, Easwaralingam N*, Warrier S, Mak C, Carson E, Ong A, Snook K, Middleton K, Parker A, Spillane A, Mann B, Lim E*, Segara D.* Window of Opportunity Treatment in Breast Cancer. ANZ J Surg. 2020 Jan;90(1-2):34-40.

Chi D, Singhal H, Li L, Xiao TF, Liu WH, Pun M, Jeselsohn R, He H, Lim E, et al. Estrogen Receptor Signaling is Reprogrammed During Breast Tumorigenesis. Proc Natl Acad Sci USA. 2019 Jun 4;116(23):11437-43.

Kennedy SP, Han JZR, Portman N, Nobis M, Hastings JF, Murphy KJ, Latham SL, Cadell AL, Miladinovic D, Marriott GR, O'Donnell YEI, Shearer RF, Williams JT, Munoz AG, Cox TR, Watkins DN, Saunders DN, Timpson P, Lim E, Kolch W, Croucher DR. Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer. Breast Cancer Res. 2019;21(1):43.

Chia KM, Milioli H, Portman N, Laven-Law G, Coulson R, Yong A, Segara D, Parker A, Caldon CE, Deng N, Swarbrick A, Tilley WD, Hickey TE*, Lim E*. Non-canonical AR activity facilitates endocrine resistance in breast cancer. Endocr Relat Cancer. 2019 Feb 1;26(2):251-64

Young AR, Duarte JD, Coulson R, O’Brien M, Deb S, Lopata A, Behren A, Mathivanan S, Lim E, Meeusen E. Immunoprofiling of Breast Cancer Antigens Using Antibodies Derived from Local Lymph Nodes. Cancers. 2019 May 16;11(5):682

Grossmann M, Ramchand SK, Milat F, Vincent A, Lim E, et al. Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Summary Position Statement. Med J Aus. 2019; 211(5):224-9

Grossmann M, Ramchand S, Milat F, Vincent A, Lim E, et al. Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia. Clinical Endo. 2018 Sep;89(3):280-96.

Portman N, Alexandrou S, Carson EK, Wang S, Lim E*, Caldon CE*. Overcoming CDK4/6 inhibitor resistance in ER positive breast cancer. Endocr Relat Cancer. 2019 Jan;26(1):R15-30

Cazet AS, Hui MH, Elsworth BL, Wu SZ, Roden D, Chan CL, Skhinas JN, Collot R, Yang J, Harvey K, Johan MZ, Cooper C, Nair R, Herrmann D, McFarland A, Deng NT, Ruiz-Borrego M, Rojo F, Trigo JM, Bezares S, Caballero R, Lim E, et al. Targeting stromal remodeling and cancer stem cell plasticity to overcome chemoresistance in triple negative breast cancer. Nature Comms. 2018 Jul 24;9(1):2897

Papachristou E, Kishore K, Holding A, Harvey K, Roumeliotis T, Chilamakuri C, Omarjee S, Chia KM, Swarbrick A, Lim E, et al. Quantitative Multiplexed Rapid Immunoprecipitation Mass spectrometry of Endogenous proteins (qPLEX-RIME) for monitoring the dynamics of chromatin-associated complexes. Nature Comms. 2018 Jun 13;9(1):2311.

Hastie R, Lim E, et alVinorelbine potently induces placental cell death, does not harm fertility and is a potential oral treatment for ectopic pregnancy. EBioMedicine. 2018;29:166-76.

Roswall P, Bocci M, Bartoschek M, Li H, Kristiansen G,  Jansson S, Larsson C, Eriksson P, Lehn S, Reid S, Saal LH, Anderberg C, Cortez E, Cordero E, Haller BK,  Häkkinen J, Burvenich IJG, Lim E, et al. Microenvironmental control of breast cancer subtype elicited by paracrine platelet derived growth factor-CC signaling. Nature Medicine. 2018;24(4):463-73.

Robinson DH, Churilov L, Lin NU, Lim E*, Seah D*. Attitudes of patients with metastatic cancer towards research biopsies. APac JCO. 2017 Nov 6.

Brockwell NK, Owen KL, Zanker D, Spurling A, Rautela J, Duivenvoorden HM, Baschuk N, Caramia F, Loi S, Darcy PK, Lim E, Parker BS. Neoadjuvant interferons: Critical for effective PD-1 based immunotherapy in TNBC. Cancer Immunol Res. 2017;5(10):871-884

Meeusen E, Lim E, Mathivanan S. Secreted Tumor Antigens – Immune Biomarkers for Diagnosis and Therapy. Proteomics. 2017 Dec 17.

Lim E, Johnson SF, Geyer M, Serra V, Shapiro GI. Sensitizing HR-proficient cancers to PARP inhibitors. Molecular Cellular Oncology. 2017 Mar 3.

Law A, Lim E, Ormandy CJ, Gallego-Ortega D. The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. Endo Rel Cancer. 2017;24(4):R123-44

Dreijerink K, Groner AC, Vos E, Font-Tello A, Gu L, Chi D, Reyes J, Cook J, Lim E, et al. Enhancer-mediated oncogenic function of the MEN1 tumor suppressor in breast cancer. Cell Reports. 2017;18(10):2359-72

Haupt S, Vijayakumaran R, Panimaya J, Burgess A, Lim E, Haupt Y. The role of MDM2 and MDM4 in breast cancer development and prevention. J Mol Cell Biol. 2017 Jan 17.

Johnson SF, Cruz C, Greifenberg AK, Dust S, Stover DG, Chi D, Primack B, Cao S,  Bernhardy AJ, Coulson R, Lazaro JB, Kachupurakkal B, Sun H, Unitt C, Moreau LA, Sarosiek KA, Scaltriti M, Juric D, Baselga J, Richardson AL, Rodig SJ, D’Andrea AD, Balmaña J, Johnson N, Geyer M, Serra V, Lim E, and Shapiro GI.  CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild type and mutated models of triple negative breast cancer. Cell Reports. 2016;17(9):2367-2381

Lim E, Tarulli G, Portman N, Hickey T, Tilley W, Palmeiri C. Pushing the Estrogen Receptor Around in Breast Cancer. Endocrine Related Cancers. 2016;23(12):T227-T24

Lim E, Palmieri C, Tilley W. Renewed interest in the Progesterone Receptor in Breast Cancer. British J Cancer. 2016 Sep 22.

Portman N, Wahlroos S, Parker A, Segara D, Lim E. Endocrine therapy for breast cancer: A Renaissance. The Endocrinologist. Dec 2016.

Burgess A, Chia KM, Haupt S, Thomas D, Haupt Y, Lim E. Clinical Overview of MDM2/X targeted therapies. Frontiers Onc 2016:6:1-7.

Chaffer CL, San Juan BP, Lim E, Weinberg RA. EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 2016 Nov 22.

Neupane M, Clark A, Landini S, Birkbak N, Eklund A, Lim E, et al. MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism that Mimics the Role of Activated RAS in Malignancy. Cancer Discovery. 2016:6(1):45-58.

Samanta S, Sun H, Goel HL, Pursell B, Chang C, Khan A, Greiner DL, Cao S, Lim E, Shultz LD, Mercurio AM. IMP3 Promotes Stem-like Properties in Triple-Negative Breast Cancer by Regulating SLUG. Oncogene 2016;35(9):1111-21.

Chia KM, O’Brien M, Brown M, Lim E. Targeting the androgen receptor in breast cancer. Current Oncology Reports. 2015;17(2):427-34

Wang YB, Zhang T, Kwiatkowski N, Abraham BJ, Lee TI, Xie S, Yuzugullu H, Von T, Li H, Lin Z, Stover DG, Lim E, et al. CDK7-dependent transcriptional addiction in Triple-Negative breast cancer. Cell 2015;163(1):174-86.

Wee ZN, Yatim SM, Kohlbauer VK, Feng M, Goh JY, Yi B, Lee PL, Zhang S, Wang PP, Lim E, et al. IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nature Comms. 2015 Oct 27;6:8746

Chang C, Goel HL, Gao H, Pursell B, Shultz LD, Greiner DL, Ingerpuu S, Patarroyo M, Cao S, Lim E, et al. A Laminin 511 Matrix is Regulated by TAZ and Functions as the Ligand for the a6Bb1 Integrin to Sustain Breast Cancer Stem Cells. Genes & Dev. 2015;29(1):1-6.

Hu Y, Petit A, Ficarro S, Toomire KJ, Xie A, Lim E, et al. PARP1-driven Poly-ADP-ribosylation regulates BRCA1 function in homologous recombination mediated DNA repair. Cancer Discovery. 2014;4(12):1430-47.

Lim E, Ni M, Cao SA, Hazra A, Tamimi R, Brown M. Importance of breast cancer subtype in the development of androgen receptor directed therapy. Current Breast Cancer Reports. 2014:6(2):71-8.

Chen X, Iliopoulos D, Zhang Q, Tang Q, Greenblatt MB, Hatziapostolou M, Lim E, et al. XBP1 promotes triple negative breast cancer by controlling the HIF1α transcriptional program. Nature. 2014:508(7494):103-7.

Wang YB, Lee YM, Huang A, Lim E, et al. The oncogenic protein kinase MELK is essential for mitotic progression in basal-like breast cancer cells. Elife. 2014:May20:3:e01763.

Lim E & Lin NU. Updates on the management of breast cancer brain metastases. Oncology. 2014:28(7):572-8.

Lu G, Zhang Q, Huang Y, Song JX, Tomaino R, Ehrenberger T, Lim E, et al. Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor. Cancer Cell. 2014:26(2):222-34.

Tam WL, Lu H, Buikhuisen J, Soh BS, Lim E, et al. Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell. 2013:24(3):347-64.

Ni M, Chen YW, Fei T, Li D, Lim E, Liu XS, Brown M. Amplitude modulation of androgen signaling by c- MYC. Genes Dev. 2013:27(7):734-48.

McLaughlin SK, Olsen SN, Dake B, De Raedt T, Lim E, et al. The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell. 2013:24(3):365-78.

Buchwalter G, Hickey MM, Cromer A, Selfors LM, Gunawardane RN, Frishman J, Jeselsohn R, Lim E, et al. PDEF Promotes Luminal Differentiation 1 and acts as a survival factor for ER positive breast cancer cells. Cancer Cell. 2013;23;753–67.

Tichy J, Lim E, Anders CK. Adolescent and young adult breast cancer: A review with a focus on biology. J Natl Compr Canc Netw. 2013:11(9):1060-9.

Lim E, Metzger O, Winer EP. Natural history of hormone receptor positive breast cancer. Oncology. 2012:26(8):688-94.

Lim E, Ni Min, Hazra A, Tamini R, Brown M. Elucidating the role of androgen receptors and breast cancer. Clinical Investigation. 2012:2(10):1003-11

Lim E & Lin NU. New insights and emerging therapies in breast cancer brain metastases. Oncology. 2012:26(7):652-9.

Shen R, Zhou A, Kim E, Lim E, Habelhah H, Hahn W. IKKε phosphorylates TRAF2 to promote mammary epithelial cell transformation. Mol Cell Biol. 2012:32(23):4756-68.

Oakes SR, Vaillant F, Lim E, et al. The BH3-mimetic ABT-737 sensitizes BCL-2 expressing breast cancers to chemotherapy, implicating BCL-2 as a predictive biomarker. PNAS. 2011:109(8):2766-71.

Ni M, Chen YW, Lim E, et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell. 2011:20(1):119-31.

Lim E & Winer EP. Will preoperative trials change future clinical practice? Clinical Investigation. 2011:1(1):59-73.

Lim E & Winer EP. Adjuvant chemotherapy in luminal breast cancers. Breast. 2011:20(S3):S128-31.

Lim E, Wu D, Pal B, Bouras T, Asselin-Labat ML, Vaillant F, et al. Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res. 2010:12(2):R21.

Wu D, Lim E, et al. ROAST: rotation gene set tests for complex microarray experiments. Bioinformatics. 2010:26(17):2176-82.

Lim E, Vaillant F, Wu D, et al. Aberrant luminal progenitors as a likely target population for basal tumor development in BRCA1 mutation carriers. Nature Med. 2009:15(8):842-4.


More Garvan Publications